62259-93-2

Basic information

• Product Name: Pyrido[3,4-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-phenyl-7-(phenylmethyl)-
• Synonyms: Pyrido[3,4-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-phenyl-7-(phenylmethyl)-;5,6,7,8-Tetrahydro-2-phenyl-7-benzylpyrido[3,4-d]pyrimidin-4(3H)-one;7-benzyl-2-phenyl-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4(3H)-one
• CAS NO: 62259-93-2
• Molecular Formula: C₂₀H₁₉N₃O
• Molecular Weight: 317.38
• Mol File: 62259-93-2.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Density: 1.23
• CAS DataBase Reference: Pyrido[3,4-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-phenyl-7-(phenylmethyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyrido[3,4-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-phenyl-7-(phenylmethyl)-(62259-93-2)
• EPA Substance Registry System: Pyrido[3,4-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-phenyl-7-(phenylmethyl)-(62259-93-2)

Safety Data

• Hazardous Substances Data: 62259-93-2(Hazardous Substances Data)

Usage

General Description

Pyrido[3,4-d]pyrimidin-4(3H)-one, 5,6,7,8-tetrahydro-2-phenyl-7-(phenylmethyl)- is a complex chemical compound with a unique structure. It is composed of a pyrido[3,4-d]pyrimidin-4(3H)-one core, with a 5,6,7,8-tetrahydro-2-phenyl-7-(phenylmethyl)- substitution on the ring. This chemical is classified as a heterocyclic compound, and its specific properties and uses are not immediately evident from the name alone. It may have potential pharmaceutical applications or be used as a building block in organic synthesis. Further research and analysis would be required to fully understand the properties and potential uses of this compound.

Upstream product

• 1670-14-0 benzamidine monohydrochloride 
• 52763-21-0 ethyl 1-benzyl-3-oxopiperidine-4-carboxylate hydrochloride 

Downstream Products

• 849776-96-1 C₂H₄O₂*C₁₃H₁₃N₃O 
• 16081-85-9 2-phenylpyrido[3,4-d]pyrimidin-4(3H)-one 
• 849776-89-2 C₁₈H₁₃N₅ 
• 849777-02-2 C₁₃H₈ClN₃ 

Relevant articles and documents

QUINAZOLINE DERIVATIVES AS MEDICAMENTS

Quinazoline derivatives have the formula (I) or the pharmaceutically acceptable salts thereof; wherein each of Z5, Z6, Z7 and Z8 is N or CH and wherein one or two Z5, Z6, Z7 and Z8 are N and wherein two adjacent Z positions cannot be N; wherein m and n are each independently 0-3; wherein R1 is independently OH, SH, NH2, OR, SR, NHR, halo or R-halide; wherein two adjacent R1 groups may be joined to form an aliphatic hetero cycle ring of 5-6 members; wherein R2 is independently R, halo, R-halide, OR-halide, NH2, CONH2 or CONHR; wherein R is optionally substituted C1-C12 alkyl, C1-C12 alkenyl, C1-C12 alkynyl, or aryl C1-C12 alkyl, containing 0-4 heteroatoms in place of a carbon in the carbon backbone, where the optional substituents are =O, =N, or OH; and wherein R3 is H or CH3. Such compounds are useful in pharmaceutical compositions and methods of treating conditions characterized by enhanced TGFβ activity.